Hereditary genetic disorders, cancer, and infectious diseases of the liver affect millions of
people around the globe and are a major public health burden. Most contemporary …

Gene therapy is a promising strategy for the treatment of monogenic disorders. Non-viral
gene delivery systems including lipid-based DNA therapeutics offer the opportunity to …

Nanoparticles are becoming an increasingly popular tool for biomedical imaging and drug
delivery. While the prevalence of nanoparticle drug-delivery systems reported in the …

Surface charge plays a fundamental role in determining the fate of a nanoparticle, and any
encapsulated contents, in vivo. Herein, we describe, and visualise in real time, light …

Despite the common knowledge that the reticuloendothelial system is largely responsible for
blood clearance of systemically administered nanoparticles, the sequestration mechanism …

The recent approval of Onpattro® and COVID-19 vaccines has highlighted the value of lipid
nanoparticles (LNPs) for the delivery of genetic material. If it is known that PEGylation is …

Circulation lifetime is a crucial parameter for a successful therapy with nanoparticles.
Reduction and alteration of opsonization profiles by surface modification of nanoparticles is …

Lipid nanoparticles (LNPs) are becoming widely adopted as vectors for the delivery of
therapeutic payloads but generally lack intrinsic tissue-homing properties. These …

Lipid‐based nanocarriers have demonstrated high interest in delivering genetic material,
exemplified by the success of Onpattro and COVID‐19 vaccines. While PEGylation imparts …

Among various nanocarriers, liposomes, and micelles are relatively mature drug delivery
systems with the advantages of prolonging drug half-life, reducing toxicity, and improving …